Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGEN Stock Forecast 2026-2027
$130.59
Current Price
$7.37B
Market Cap
Buy 18
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to RGEN Price Targets
+68.5%
To High Target of $220.00
+37.8%
To Median Target of $180.00
+8.7%
To Low Target of $142.00
RGEN Price Momentum
+4.2%
1 Week Change
+26.9%
1 Month Change
+2.4%
1 Year Change
-20.3%
Year-to-Date Change
-25.7%
From 52W High of $175.77
+29.3%
From 52W Low of $100.99
📊 TOP ANALYST CALLS
Did RGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Repligen is one of their latest high-conviction picks.
Latest RGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RGEN has a bullish consensus with a median price target of $180.00 (ranging from $142.00 to $220.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $130.59, the median forecast implies a 37.8% upside. This outlook is supported by 18 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGEN Analyst Ratings
18
Buy
4
Hold
0
Sell
RGEN Price Target Range
Low
$142.00
Average
$180.00
High
$220.00
Current: $130.59
Latest RGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | HSBC | Sidharth Sahoo | Buy | Maintains | $150.00 |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $145.00 |
| May 15, 2026 | RBC Capital | Dan Leonard | Outperform | Reinstates | $160.00 |
| May 6, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 6, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 20, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Apr 17, 2026 | Roth Capital | Buy | Initiates | $N/A | |
| Apr 14, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 25, 2026 | UBS | Buy | Maintains | $N/A | |
| Feb 25, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jan 16, 2026 | UBS | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 15, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 29, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Oct 29, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Oct 7, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A |
Repligen Corporation (RGEN) Competitors
The following stocks are similar to Repligen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Repligen Corporation (RGEN) Financial Data
Repligen Corporation has a market capitalization of $7.37B with a P/E ratio of 143.5x. The company generates $763.34M in trailing twelve-month revenue with a 6.7% profit margin.
Revenue growth is +14.8% quarter-over-quarter, while maintaining an operating margin of +8.9% and return on equity of +2.5%.
Valuation Metrics
Market Cap
$7.37B
Enterprise Value
$7.27B
P/E Ratio
143.5x
PEG Ratio
2.9x
Price/Sales
9.7x
Growth & Margins
Revenue Growth (YoY)
+14.8%
Gross Margin
+55.7%
Operating Margin
+8.9%
Net Margin
+6.7%
EPS Growth
+42.9%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
9.2x
Debt/Equity
32.7x
ROE
+2.5%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Repligen Corporation (RGEN) Business Model
About Repligen Corporation
What They Do
Develops bioprocessing technologies for biologic drugs.
Business Model
Repligen Corporation generates revenue by providing advanced bioprocessing technologies and systems to biopharmaceutical companies and contract development organizations. Their product offerings span filtration, chromatography, proteins, and process analytics, which are essential for the manufacturing of complex biologic drugs, including monoclonal antibodies and gene therapies.
Additional Information
Headquartered in Waltham, Massachusetts, Repligen serves clients across North America, Europe, and Asia Pacific. The company focuses on addressing critical needs in the biologics production process, ensuring efficiency and effectiveness in drug manufacturing for emerging therapies.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,778
CEO
Mr. Olivier Loeillot
Country
United States
IPO Year
1990
Website
www.repligen.comRepligen Corporation (RGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript
11 days ago
Quick Summary
Repligen Corporation (RGEN) presented at the 46th Annual William Blair Growth Stock Conference, discussing its growth strategies and business performance.
Why It Matters
Repligen's presentation at a notable investment conference can signal growth potential and attract investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Repligen (RGEN) reported earnings 30 days ago; investors should monitor upcoming developments that could impact the stock's performance.
Why It Matters
Repligen's recent earnings report may signal upcoming stock performance trends, influencing investor sentiment and potential trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
In Q1 2026, the largest portfolio sectors were Health Care and Industrials. Top performers included RBC Bearings, Cognex, and Nebius, while Repligen, Agilysys, and GeneDx underperformed.
Why It Matters
The sector weightings signal where market strength lies, while the performance of specific companies highlights potential investment opportunities and risks within those sectors.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Repligen's Q1 2026 revenue rose 15%, with 11% from organic growth, indicating recovery after a challenging 2024. Key factors include Polymem, China, PAT, and the Transformation Office.
Why It Matters
Repligen's Q1 revenue growth signals a recovery, highlighting potential for future profitability. Key initiatives suggest improved operational efficiency, impacting investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Repligen Corporation (NASDAQ:RGEN) will present at the William Blair 46th Annual Growth Stock Conference on June 3rd at 10:40 a.m. CT, led by CEO Olivier Loeillot.
Why It Matters
Repligen's participation in a prominent conference signals potential growth opportunities and investor interest, which can impact stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Repligen Corporation (NASDAQ:RGEN) released its 2025 Corporate Sustainability Report, highlighting progress in sustainability across six areas and aligning with UN SDGs and major reporting frameworks.
Why It Matters
Repligen's sustainability report highlights its commitment to responsible growth and alignment with global standards, potentially enhancing its reputation and attracting environmentally-conscious investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RGEN Stock
What is Repligen Corporation's (RGEN) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Repligen Corporation (RGEN) has a median price target of $180.00. The highest price target is $220.00 and the lowest is $142.00.
Is RGEN stock a good investment in 2026?
According to current analyst ratings, RGEN has 18 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $130.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGEN stock?
Wall Street analysts predict RGEN stock could reach $180.00 in the next 12 months. This represents a 37.8% increase from the current price of $130.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repligen Corporation's business model?
Repligen Corporation generates revenue by providing advanced bioprocessing technologies and systems to biopharmaceutical companies and contract development organizations. Their product offerings span filtration, chromatography, proteins, and process analytics, which are essential for the manufacturing of complex biologic drugs, including monoclonal antibodies and gene therapies.
What is the highest forecasted price for RGEN Repligen Corporation?
The highest price target for RGEN is $220.00 from at , which represents a 68.5% increase from the current price of $130.59.
What is the lowest forecasted price for RGEN Repligen Corporation?
The lowest price target for RGEN is $142.00 from at , which represents a 8.7% increase from the current price of $130.59.
What is the overall RGEN consensus from analysts for Repligen Corporation?
The overall analyst consensus for RGEN is bullish. Out of 5 Wall Street analysts, 18 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $180.00.
How accurate are RGEN stock price projections?
Stock price projections, including those for Repligen Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:47 AM UTC